This study examined which specific KRAS gene mutations are found in colorectal cancer patients and whether each mutation creates different weak points that drugs could target. Colorectal cancer affects about 153,000 Americans yearly, and roughly 45% have KRAS mutations. The research found that while current lab tools (screening just 4-8 cell lines per mutation type) cannot yet identify mutation-specific drug targets, the analysis confirmed the overall approach works and built a practical guide matching each KRAS mutation type to the best available or upcoming targeted therapies — from approved drugs like sotorasib for the G12C mutation to newer agents entering clinical trials for the more common G12D and G12V mutations.